Masding J, Sarkar T K, White W F, Barley V L, Chawla S L, Boesen E, Rostom A Y, Menday A P
King Edward VII Hospital, Midhurst, West Sussex.
Br J Obstet Gynaecol. 1990 Apr;97(4):342-51. doi: 10.1111/j.1471-0528.1990.tb01813.x.
In a prospective, multicentre, randomized trial, the efficacy and tolerance of treosulfan alone was compared with that of treosulfan plus cisplatinum in 135 women with advanced ovarian carcinoma. No statistically significant difference was found between the two treatments in terms of median survival. Combined treatment was associated with significantly greater side-effects and haematological toxicity. Optimal survival with minimal toxicity can be achieved by using treosulfan alone in patients (mainly stages Ic or II) with minimal postoperative residual disease. Patients (likely to be stage III or IV) with greater residual disease should receive treosulfan plus cisplatinum.
在一项前瞻性、多中心、随机试验中，对135例晚期卵巢癌女性患者比较了单用曲奥舒凡与曲奥舒凡加顺铂的疗效和耐受性。两种治疗方法在中位生存期方面未发现统计学上的显著差异。联合治疗的副作用和血液学毒性明显更大。对于术后残留疾病极少的患者（主要为Ic期或II期），单用曲奥舒凡可实现毒性最小化的最佳生存。残留疾病较多的患者（可能为III期或IV期）应接受曲奥舒凡加顺铂治疗。
